NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/29/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5,502.08 mln
Float18.48 mln
Earnings Date08/12/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
19
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-21.01
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Belite Bio is a San Diego-based drug development company focused on creating treatments for serious eye conditions that currently have few or no effective options. Its most advanced drug, Tinlarebant, is taken by mouth and is currently in Phase 3 trials for patients with Stargardt disease and geographic atrophy, two conditions that cause progressive vision loss. The company is also working on a separate oral drug targeting liver disease, type 2 diabetes, and gout. Founded in 2016, Belite Bio operates as part of Lin Bioscience International Ltd.
